<DOC>
	<DOCNO>NCT01474954</DOCNO>
	<brief_summary>This single-site substudy , `` Investigation Effect Cenicriviroc ( CVC ) plus Emtricitabine/Tenofovir ( FTC/TDF ) Atherosclerosis Risk Factors '' , open patient enrol primary study , `` A Phase 2b Randomized , Double-Blind , Double-Dummy Trial 100 200 mg Once-Daily Doses Cenicriviroc ( CVC , TBR-652 ) Once-Daily EFV , Each With Open-Label FTC/TDF , HIV-1-Infected , Antiretroviral Treatment-Naïve , Adult Patients With Only CCR5-Tropic Virus '' , San Francisco Bay area evaluate change brachial flow mediate dilation patient one three treatment group : 1 . Cenicriviroc ( CVC ) 100mg ( 2 tablet , 50mg ) QD + CVC match placebo ( 2 tablet ) QD + Efavirenz ( EFV ) match placebo ( 1 capsule ) QHS + emtricitabine/tenofovir disoproxil fumarate ( FTC/TDF ) ( 1 tablet ) QD ; 2 . CVC 200mg ( 4 tablet , 50mg ) QD + EFV match placebo ( 1 capsule ) QHS + FTC/TDF ( 1 tablet ) QD ; 3 . CVC match placebo ( 4 tablet ) QD + EFV 600 mg ( 1 capsule ) QHS + FTC/TDF ( 1 tablet ) QD . The substudy run duration primary study . 50 patient 150 total enrol primary study refer enrol cardiovascular substudy . Patients enrol substudy substudy protocol staff blind study treatment . Data obtain substudy analyze conjunction laboratory data cardiovascular disease risk factor HIV-1 RNA level obtain primary study . The primary study randomize , double-blind , double-dummy , 48-week , comparative study approximately 150 HIV-1-infected , treatment-naïve patient CCR5-tropic virus . Patients stratify Screening HIV-1 RNA level ( ≥100,000 copies/mL versus &lt; 100,000 copies/mL ) randomize 2:2:1 one three treatment group . Patients receive medication primary study , thus primary study site responsible adverse outcome drug .</brief_summary>
	<brief_title>Investigation The Effect Cenicriviroc ( CVC ) Plus FTC/TDF Cardiovascular Disease Risk Factors</brief_title>
	<detailed_description>This single-site substudy , `` Investigation Effect Cenicriviroc ( CVC ) plus Emtricitabine/Tenofovir ( FTC/TDF ) Atherosclerosis Risk Factors '' , open patient enrol primary study , `` A Phase 2b Randomized , Double-Blind , Double-Dummy Trial 100 200 mg Once-Daily Doses Cenicriviroc ( CVC , TBR-652 ) Once-Daily EFV , Each With Open-Label FTC/TDF , HIV-1-Infected , Antiretroviral Treatment-Naïve , Adult Patients With Only CCR5-Tropic Virus '' , San Francisco Bay area evaluate change brachial flow mediate dilation patient one three treatment group : 1 . Cenicriviroc ( CVC ) 100mg ( 2 tablet , 50mg ) QD + CVC match placebo ( 2 tablet ) QD + Efavirenz ( EFV ) match placebo ( 1 capsule ) QHS + emtricitabine/tenofovir disoproxil fumarate ( FTC/TDF ) ( 1 tablet ) QD ; 2 . CVC 200mg ( 4 tablet , 50mg ) QD + EFV match placebo ( 1 capsule ) QHS + FTC/TDF ( 1 tablet ) QD ; 3 . CVC match placebo ( 4 tablet ) QD + EFV 600 mg ( 1 capsule ) QHS + FTC/TDF ( 1 tablet ) QD . The substudy run duration primary study . 50 patient 150 total enrol primary study refer enrol cardiovascular substudy . Patients enrol substudy substudy protocol staff blind study treatment . Data obtain substudy analyze conjunction laboratory data cardiovascular disease risk factor HIV-1 RNA level obtain primary study . The primary study randomize , double-blind , double-dummy , 48-week , comparative study approximately 150 HIV-1-infected , treatment-naïve patient CCR5-tropic virus . Patients stratify Screening HIV-1 RNA level ( ≥100,000 copies/mL versus &lt; 100,000 copies/mL ) randomize 2:2:1 one three treatment group . Patients receive medication primary study , thus primary study site responsible adverse outcome drug . Primary Objective : · To assess change Baseline brachial artery vascular patency 24 week treatment CVC contain regimen . Secondary Objectives : - To compare change Baseline vascular patency 48 week treatment CVC versus EFV . - To assess change Baseline Weeks 4 , 12 , 24 , final follow-up vascular patency . - To assess change Baseline Week 48 flow-mediated dilation ( FMD ) relation immunologic metabolic covariates .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<criteria>Adult male female , HIV1infected patient 18 year old old . Body mass index ( BMI ) 18 &lt; =35 kg/m2 Antiretroviral treatmentnaive ( prior nonnucleoside reverse transcriptase inhibitor , woman receive single dose perinatal nevirapine K103 viral mutation , prior CCR5 antagonist therapy , 10 day prior antiretroviral therapy ) HIV1 CCR5tropiconly virus , determine tropism genotype enhance Trofile assay Plasma HIV1 RNA level &gt; = 1,000 copies/mL Screening Visit 1 CD4 count &gt; = 250 cells/mm3 Screening Visit 1 Able willing provide write informed consent Willing take appropriate precaution prevent pregnancy Women childbearing potential may enrol follow negative urine pregnancy test . If participating activity could lead pregnancy , men woman must agree use two form barrier method contraception trial 3 month stop medication . Women reproductive potential ( document surgically sterile postmenopausal [ define amenorrhea &gt; = 1 year follicle stimulate hormone &gt; = 30 mU/mL ] ) eligible enrol Signed inform consent participation substudy Presence CXCR4 dual/mixedtropic HIV1 virus either enhance Trofile assay tropism genotype Presence primary resistance mutation phenotypic resistance TDF , FTC , EFV and/or mutation associate multidrug nucleoside/nucleoside resistance An active CDC category C disease ( except cutaneous Kaposi 's sarcoma require systemic therapy trial ) Any historical CD4 count &lt; 200 cells/mm3 Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value Grade &gt; =2 total bilirubin great upper limit normal ( ULN ) Screening History HIV2 , hepatitis B and/or C , cirrhosis liver , know active chronic liver disease . Hepatitis B vaccinate patient eligible , follow : Patients recent history hepatitis B ( positive hepatitis B surface antigen [ HBsAg ] ) exclude . Patients prior exposure hepatitis B virus present ( positive hepatits B surface antibody [ HBsAb ] ) eligible provide liver function test ( AST ALT ) within normal range , patient signs/symptoms hepatitis , entry criterion meet . Patients positive hepatitis B core antibody ( HBcAb ) may chronic carrier hepatitis B clear virus eligible provide liver function test ( AST ALT ) completely normal , patient signs/symptoms hepatitis , entry criterion meet . Patients positive hepatitis C antibody ( HCVAb ) exclude , except proof viral clearance normal liver function test ( LFTs ) may eligible Medical Monitor approval . A current diagnosis tuberculosis ( TB ) infection , prior untreated TB infection , inadequate treatment active TB , inadequate treatment positive purify protein derivative ( PPD ) test . Cases active infection latent TB infection document history adequate treatment may consider enrollment provide subject negative chest xray follow treatment within 6 month randomization . Adequate treatment define meet current recommendation Centers Disease Control Prevention ( CDC ) . National Institutes Health ( NIH ) , HIV Medicine Association Infectious Diseases Society America ( IDSA ) guideline , CDC recommendation patient treat current recommendation coinfection HIV . Investigators encourage discus case Medical Monitor doubt patient eligibility . Any prior current diagnosis intracellular pathogen . Recent history ( &lt; 30 day ) clinically significant infection illness . Pregnancy breastfeed Current anticipated treatment immunmodulating agent ( systemic corticosteroid , interleukin , interferon ) agent know antiHIV activity Immunization within 30 day first dose investigational study drug . Current alcohol durg use , expert judgment Investigator , interfere patient 's ability comply protocol requirement . Any experimental medication within 30 day prior Screening anticipate use trial . Current ( within 5 halflives 14 day prior first dose study drug , whichever long ) anticipate use antimetabolites ; alkylating agent ; drug , herbal preparation ( include St. John 's wort ) , food ( include grapefruit ) know affect cytochrom P450 ( CYP ) family CYP 3A4 CYP 2C8 enzyme Pglycoprotein ( Pgp ) transporter . Use overthe counter ( OTC ) medication follow : In first 25 patient , systemic OTC preparation , include herbal preparation ( e.g . phytotherapeutic , herbal , plantderived preparation ) , within 14 day prior first dose study medication ) After first 25 patient , systemic OTC herbal medication ( include phytotherapeutic , herbal , plantderived preparation ) within 14 day prior first dose study medication , unless approve Investigator . After first 25 patient , chronically need OTC medication , unless discuss approve Medical Monitor History clinically significant metabolic , endocrine , hepatic , renal , hematologic , pulmonary , gastrointestinal , cardiovascular disorder . Uncontrolled hypertension ( i.e . systolic blood pressure [ BP ] &gt; =140 diastolic BP &gt; = 90 ) Bradycardia , define sinus rhythm &lt; 50 beats/min ( bpm ) History presence abnormal electrocardiogram ( ECG ) Presence condition would interfere absorption , distribution , metabolism , excretion drug . After first 25 patient enrol , adequately control condition gastroesophageal reflux disease ( GERD ) may allow . Investigators encourage discus case Medical Monitor doubt patient eligibility . History malignancy except cure basal squamous cell carcinoma skin Patients receive radiation cytotoxic chemotherapeutic agent , unless fully recovered time first dose study drug , may require study period . Patients , opinion Investigator , unable comply dose schedule protocol evaluation . Inability access research clinic . Inability , judgement investigator , comply additional requirement substudy . Starting , stop , change lipidlowering antihypertensive medication within 12 week study entry . Persistent rest blood pressure le 100/70 mm Hg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>Antiretroviral Medication</keyword>
	<keyword>Cardiovascular Disease Risk</keyword>
</DOC>